Migraine

The AJMC® Migraine compendium is a comprehensive resource for clinical news and expert insights for the recurring type of headache, which is accompanied by side effects.

Latest News

Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists

April 20th 2023

This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.

Image of a hurting perosn
Care for Migraine Insufficient in Germany, Online Survey Finds

March 25th 2022

woman with migraine
Comparing Benign Recurrent Vertigo With Vestibular Migraine, Menière's Disease

March 21st 2022

tech
Machine Learning Could Help Predict Migraineur Response to NSAIDs

March 17th 2022

people in hospital
Examining Trends in Headache-Related ED Visits, Treatment

March 14th 2022

Acute Migraine Treatment: Prevalence and Classes of Agents

Experts in the management of migraine discuss the prevalence of individuals taking acute migraine therapy and enumerate the various classes of agents available.

Acute and Preventive Therapy for Migraine peer exchange

More News

Express Scripts Launching Value-Based Migraine Program
October 17th 2018

Express Scripts Launching Value-Based Migraine Program

Jaime Rosenberg
Starting April 1, 2019, Express Scripts will offer its SafeGuardRx Migraine Care Value program, which will help patients achieve better outcomes with preventive therapies and offer a value-based design for plan sponsors.
Inhaler Effective for Treating Migraine Attacks, According to Pilot Study
October 12th 2018

Inhaler Effective for Treating Migraine Attacks, According to Pilot Study

Alison Rodriguez
In some instances, migraine can be treated without medicine, meaning some patients with migraine can cut down on their medication use, according to a new study that demonstrated efficacy with an inhaler that slightly changes the body’s own molecules.
CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week
October 10th 2018

CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week

Jaime Rosenberg
Researchers compiled data from 2 studies demonstrating the safety and efficacy of erenumab at 4 weeks and found that the treatment resulted in a reduction of weekly migraine days as early as week 1.
Researchers Develop Questionnaire to Assess Impact of Migraine on Work-Related Difficulties
October 4th 2018

Researchers Develop Questionnaire to Assess Impact of Migraine on Work-Related Difficulties

Alison Rodriguez
Researchers developed a set of items based on a previous literature review and patients’ focus groups and tested it on a wide set of patients with episodic and chronic migraine.
Can Patients With Migraine Predict an Attack?
September 30th 2018

Can Patients With Migraine Predict an Attack?

Jaime Rosenberg
The majority of patients who suffer from migraine experience premonitory symptoms and are able to predict at least 1 attack, according to a new study.
Regular Exercise May Reduce Frequency of Migraine, Study Finds
September 29th 2018

Regular Exercise May Reduce Frequency of Migraine, Study Finds

Alison Rodriguez
Researchers recently investigated what role exercise plays in migraine prevention and found that although exercise can trigger migraine attacks, regular exercise may have prophylactic effects on migraine frequency.
Noninvasive Vagus Nerve Stimulation Demonstrates Efficacy in Episodic Migraine
September 27th 2018

Noninvasive Vagus Nerve Stimulation Demonstrates Efficacy in Episodic Migraine

Jaime Rosenberg
A study has found that noninvasive vagus nerve stimulation can provide pain relief for up to 60 minutes after an acute attack.
Expectations for the Future Management of Migraine
September 24th 2018

Expectations for the Future Management of Migraine

New Therapies—New Promise for Patients With Migraine
September 24th 2018

New Therapies—New Promise for Patients With Migraine

Considerations for Using CGRP Receptor Antagonists for Migraine
September 24th 2018

Considerations for Using CGRP Receptor Antagonists for Migraine

Coverage for CGRP Receptor Antagonists for Migraine
September 24th 2018

Coverage for CGRP Receptor Antagonists for Migraine

Neurostimulation Therapy for Migraine
September 24th 2018

Neurostimulation Therapy for Migraine

Novel Therapies in the Pipeline for Migraine
September 24th 2018

Novel Therapies in the Pipeline for Migraine

Anti-CGRP Therapy for Migraine: Cost Considerations
September 24th 2018

Anti-CGRP Therapy for Migraine: Cost Considerations

Using Erenumab in Clinical Practice
September 24th 2018

Using Erenumab in Clinical Practice

Erenumab in Migraine Therapy: Clinical Data
September 24th 2018

Erenumab in Migraine Therapy: Clinical Data

Migraine Treatment: Targeting CGRP
September 24th 2018

Migraine Treatment: Targeting CGRP

Resources to Facilitate the Management of Migraine
September 24th 2018

Resources to Facilitate the Management of Migraine

Preventive Therapy in Migraine: Payer Considerations
September 24th 2018

Preventive Therapy in Migraine: Payer Considerations

Preventive Measures in Migraine Management
September 24th 2018

Preventive Measures in Migraine Management

Concerns Surrounding Migraine Medication Misuse
September 24th 2018

Concerns Surrounding Migraine Medication Misuse

Strategies for Treating Migraine
September 24th 2018

Strategies for Treating Migraine

Clinical and Economic Burden of Migraine
September 24th 2018

Clinical and Economic Burden of Migraine

Challenges in Diagnosing a Migraine
September 24th 2018

Challenges in Diagnosing a Migraine

Distinguishing a Migraine From a Headache
September 24th 2018

Distinguishing a Migraine From a Headache

Researchers Assess Myofascial Trigger Points in Migraine and Tension-Type Headaches
September 22nd 2018

Researchers Assess Myofascial Trigger Points in Migraine and Tension-Type Headaches

Alison Rodriguez
Myofascial trigger points are prevalent in both migraine and tension-type headaches. However, their role in the pathophysiology of each disorder and to what degree is unclear.
Survey: Women Lack Confidence in Insurers, Employers to Meet the Needs of People With Migraine
September 17th 2018

Survey: Women Lack Confidence in Insurers, Employers to Meet the Needs of People With Migraine

Jaime Rosenberg
The survey of more than 340 women revealed an overwhelming belief that people with migraine are dismissed as exaggerating their symptoms and that employers don't understand the burden of migraine on their employees.
Prolonged Aura in Migraine Is Frequent, Similar to Other Auras
September 14th 2018

Prolonged Aura in Migraine Is Frequent, Similar to Other Auras

Alison Rodriguez
A recent study has found that prolonged auras are common and are phenotypically similar to other auras. Based on the observed duration of aura symptoms, the researchers suggest reconsidering the use of the term “prolonged aura."
Prevalence of Acute Medication Use, Overuse, and Discontinuation Among Patients With Migraine
September 11th 2018

Prevalence of Acute Medication Use, Overuse, and Discontinuation Among Patients With Migraine

Jaime Rosenberg
Two studies presented at the PAINWeek conference in Las Vegas, Nevada, took a look into the prevalence of acute medication use and overuse among migraineurs, as well as rates of medication discontinuation due to lack of efficacy or side effects.
electroCore Unveils New Version of Noninvasive Vagus Nerve Stimulator for Migraine Pain
September 8th 2018

electroCore Unveils New Version of Noninvasive Vagus Nerve Stimulator for Migraine Pain

Jaime Rosenberg
GammaCore Sapphire, the newest version of gammaCore—a noninvasive vagus nerve stimulator—is now available in the United States to treat patients with migraine and episodic cluster headache.
<1
...
1011121314151617>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo